The detailed schedule and plan for vaccination in Korea was announced, and a limited vaccination discussion continues overseas due to the lack of clinical data for AstraZeneca (AZ)'s COVID-19 vaccine, and the results of the review by licensing authorities are drawing attention later.

The MFDS will take all these into account and conduct a statistical review, but will review all the data inferring the effectiveness of the company to determine the final approval.

Sang-Bong Kim, Director of Bio-Pharmaceutical Bureau of the MFDS explained this through a regular briefing of COVID-19 during the day on the 28th.

Currently, the MFDS is in the process of reviewing as AZ applied for